Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Ohsawa F, Yamada S, Yakushiji N, Shinozaki R, Nakayama M, Kawata K, Hagaya M, Kobayashi T, Kohara K, Furusawa Y, Fujiwara C, Ohta Y, Makishima M, Naitou H, Tai A, Yoshikawa Y, Yasui H, Kakuta H. Ohsawa F, et al. Among authors: kawata k. J Med Chem. 2013 Mar 14;56(5):1865-77. doi: 10.1021/jm400033f. Epub 2013 Feb 20. J Med Chem. 2013. PMID: 23391145
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
Kakuta H, Yakushiji N, Shinozaki R, Ohsawa F, Yamada S, Ohta Y, Kawata K, Nakayama M, Hagaya M, Fujiwara C, Makishima M, Uno S, Tai A, Maehara A, Nakayama M, Oohashi T, Yasui H, Yoshikawa Y. Kakuta H, et al. Among authors: kawata k. ACS Med Chem Lett. 2012 Apr 9;3(5):427-32. doi: 10.1021/ml300055n. eCollection 2012 May 10. ACS Med Chem Lett. 2012. PMID: 24900488 Free PMC article.
Interspecies comparison of hepatic metabolism of six newly synthesized retinoid X receptor agonistic compounds possessing a 6-[N-ethyl-N-(alkoxyisopropylphenyl)amino]nicotinic acid skeleton in rat and human liver microsomes.
Murakami Y, Shimizu Y, Ogasawara A, Ueshima S, Nakayama M, Kawata K, Kakuta H, Aiba T. Murakami Y, et al. Among authors: kawata k. Drug Dev Ind Pharm. 2014 Aug;40(8):1065-71. doi: 10.3109/03639045.2013.807278. Epub 2013 Jun 19. Drug Dev Ind Pharm. 2014. PMID: 23781857
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: kawata k. J Gastroenterol Hepatol. 2025 Jan 22. doi: 10.1111/jgh.16884. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39844393
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: kawata k. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727 Free PMC article.
598 results